Page last updated: 2024-11-04

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4553
CHEMBL ID7162
CHEBI ID73458
SCHEMBL ID214213
MeSH IDM0216100

Synonyms (78)

Synonym
n-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide
bdbm50029593
n-[2-(cyclohexyloxy)-4-nitrophenyl]methane sulfonamide
n-{2-(cyclohexyloxy)-4-[hydroxy(oxido)amino]phenyl}methanesulfonamide
n-(2-cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide(ns-398)
n-(2-cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide
BRD-K53364951-001-02-6
methanesulfonamide, n-(2-(cyclohexyloxy)-4-nitrophenyl)-
ns 398
tocris-0942
BIO2_000952
BIO2_000472
NCGC00024892-01
BSPBIO_001264
IDI1_002227
ns-398
ns-398, >=98% (hplc), solid
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
NCGC00024892-02
KBIO2_003172
KBIOSS_000604
KBIO3_001068
KBIO3_001067
KBIO2_005740
KBIO2_000604
KBIOGR_000604
NCGC00024892-03
123653-11-2
ns398
n-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide
HMS1990P05
chebi:73458 ,
CHEMBL7162 ,
HMS1362P05
HMS1792P05
AKOS015965848
9sp55km2ks ,
unii-9sp55km2ks
ccris 8523
taisho ns 398
AKOS015900136
S8433
SCHEMBL214213
HY-13913
CS-5335
n-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
AC-32669
HMS3649O13
HMS3403P05
mfcd00882995
DTXSID8041084
gtpl8976
J-004968
sr-01000597479
SR-01000597479-1
n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide
n-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide
NS4 ,
KTDZCOWXCWUPEO-UHFFFAOYSA-N ,
BCP18285
ns-398 - cas 123653-11-2
FT-0719317
ns-398 (ns398)
EX-A2402
DB14060
SR-01000597479-2
n-[2-(cyclohexyloxy)-4-nitrophenyl]methane-sulfonamide
Q6955228
A13116
HMS3886L10
CCG-267631
A857428
C71930
BN163753
N1152
cyclohexyloxy-4-nitrophenyl)methanesulfonamide, n-(2-
taisho ns-398
methanesulfonamide, n-[2-(cyclohexyloxy)-4-nitrophenyl]-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Since assessment of the acute gastrotoxicity of nonsteroidal antiinflammatory drugs (NSAIDs) in rats requires high doses of the drugs, we sought to establish an experimental model with which this adverse NSAID effect can be estimated at therapy-relevant doses."( Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses.
Cabré, F; Holzer, P; Jocic, M; Mauléon, D, 2001
)
0.31
" There was no significant difference in the gastrotoxicity of FBP when the drug was administered subcutaneously or IG, whereas subcutaneously injected R/S-KP was slightly more toxic than IG R/S-KP."( Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses.
Cabré, F; Holzer, P; Jocic, M; Mauléon, D, 2001
)
0.31
" The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class."( Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity.
Klegeris, A; McGeer, PL,
)
0.13
" Our experimental results suggest that the altered expression of calpain proteins may contribute to the adverse effects of NSAIDs on intestinal epithelial restitution."( Drug-induced alterations to gene and protein expression in intestinal epithelial cell 6 cells suggest a role for calpains in the gastrointestinal toxicity of nonsteroidal anti-inflammatory agents.
Freeman, LC; Ganta, S; Lillich, JD; Narvaez, D; Raveendran, NN; Silver, K; Weng, K, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"We studied the effects of inhibitors of COX-2 (NS398) and iNOS (aminoguanidine) alone or in combination with olfactory ensheathing cell (OEC) grafts after spinal cord injury in the rat."( Effects of COX-2 and iNOS inhibitors alone or in combination with olfactory ensheathing cell grafts after spinal cord injury.
Casas, C; Forés, J; García-Alías, G; Guzmán-Lenis, MS; López-Vales, R; Navarro, X; Verdú, E, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Northern blots revealed concomitant increases in PGHS-2 mRNA levels that peaked at 2 h and were dependent on the dosage of IL-1 beta."( Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures.
Chang, JW; Coleman, PD; Kaplan, MD; Miller, JC; O'Banion, MK, 1996
)
0.29
"The anti-inflammatory effects of therapeutic dosing of drugs with greater selectivity for the inhibition of the constitutive (COX-1) or inducible isoform (COX-2) of cyclooxygenase were assessed in a model of chronic inflammation."( Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation.
Gilroy, DW; Tomlinson, A; Willoughby, DA, 1998
)
0.3
" NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform."( Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation.
Gilroy, DW; Tomlinson, A; Willoughby, DA, 1998
)
0.3
" However, they shifted the morphine antinociceptive dose-response curve to the left when coadministered with morphine during tolerance induction, and reduced the increase in the ED50 of morphine (dose producing 50% of the maximum response) three- to four-fold."( Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats.
Chou, R; Chou, YY; Hsu, MM; Tung, CS; Wong, CS, 2000
)
0.31
" In HLPs perfused with homologous blood, dose-response curves for the haemodynamic and bronchial effects of PAF (1 - 32 ng) were carried out in the absence or presence of L-NNA (200 microM)."( Nitric oxide (NO) modulation of PAF-induced cardiopulmonary action: interaction between NO synthase and cyclo-oxygenase-2 pathways.
Calabrese, R; del Basso, P; Fabi, F; Stati, T, 2001
)
0.31
" In this study, NS-398, a specific COX-2 inhibitor, and indomethacin, a COX-1 and COX-2 inhibitor, were administered 24 h after chloroform dosing to determine their effect on liver injury in Sprague-Dawley rats."( Late administration of COX-2 inhibitors minimize hepatic necrosis in chloroform induced liver injury.
Begay, CK; Gandolfi, AJ, 2003
)
0.32
" This study was designed to determine if the addition of NS-398 to NPe6-induced PDT in single or fractionated dosing would result in greater tumor kill."( Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398.
Fromm, D; Harvey, EH; Kessel, D; Webber, J, 2005
)
0.33
"Fractionated dosing of NPe6 demonstrated the best tumor kill."( Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398.
Fromm, D; Harvey, EH; Kessel, D; Webber, J, 2005
)
0.33
" Although the absolute values were similar, the dose-response curves to ANG II were different."( Angiotensin II-induced calcium signaling in the afferent arteriole from rats with two-kidney, one-clip hypertension.
Helle, F; Iversen, BM; Vågnes, ØB, 2006
)
0.33
" Platelet aggregation induced by ADP and dosing of prostanoid products 6-keto-PGF1alpha, TXB2, PGE2 and LTB4 were also performed."( Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension.
Aguejouf, O; Belon, P; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2007
)
0.34
" This paper studies the effect of the lower end of the aspirin dose-response curve, its possible mechanism and clinical implications."( Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals.
Aguejouf, O; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
cyclooxygenase 2 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (42)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
USP1 protein, partialHomo sapiens (human)Potency28.18380.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency38.36360.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency23.75300.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency8.43680.531815.435837.6858AID504845
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.05010.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.07940.00255.840031.6228AID899
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
survival motor neuron protein isoform dHomo sapiens (human)Potency4.46680.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E synthaseHomo sapiens (human)IC50 (µMol)17.50000.00102.030810.0000AID620116; AID637532; AID637535; AID717377
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)76.50000.00051.41288.2000AID399404; AID399405
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)120.33330.00032.177410.0000AID1125137; AID1125684; AID1195152; AID1322365; AID162015; AID162016; AID162021; AID162143; AID1801084; AID510444; AID683092
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)10.00000.00011.68479.3200AID6732
AromataseHomo sapiens (human)IC50 (µMol)0.68000.00001.290410.0000AID260816; AID320936
Prostaglandin G/H synthase 1Mus musculus (house mouse)IC50 (µMol)32.68500.00072.08445.1000AID161998; AID457533
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)88.83330.00021.557410.0000AID1173021; AID161335; AID161674; AID161677; AID402403
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)53.00000.00020.552110.0000AID399405
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)53.00000.00120.48289.0000AID399405
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)12.56320.00010.995010.0000AID1125138; AID1125685; AID1173017; AID1195153; AID1322366; AID1532665; AID1532669; AID162346; AID162497; AID162641; AID162665; AID162669; AID1801084; AID336477; AID340310; AID402402; AID403340; AID46852; AID46853; AID491942; AID54710; AID683093
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)26.70000.00101.453910.0000AID399405; AID427630; AID475085; AID510445; AID688618
Prostaglandin G/H synthase 2Mus musculus (house mouse)IC50 (µMol)0.15220.00050.40086.2000AID1125683; AID160570; AID418268; AID457534; AID46861; AID46862
Carboxypeptidase B2Homo sapiens (human)IC50 (µMol)1.80000.00150.54291.8000AID1322366
Prostaglandin E synthaseMus musculus (house mouse)IC50 (µMol)0.00700.00700.00700.0070AID1322364
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (119)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin E synthaseHomo sapiens (human)
prostaglandin metabolic processProstaglandin E synthaseHomo sapiens (human)
signal transductionProstaglandin E synthaseHomo sapiens (human)
cell population proliferationProstaglandin E synthaseHomo sapiens (human)
negative regulation of cell population proliferationProstaglandin E synthaseHomo sapiens (human)
sensory perception of painProstaglandin E synthaseHomo sapiens (human)
regulation of fever generationProstaglandin E synthaseHomo sapiens (human)
positive regulation of prostaglandin secretionProstaglandin E synthaseHomo sapiens (human)
regulation of inflammatory responseProstaglandin E synthaseHomo sapiens (human)
cellular oxidant detoxificationProstaglandin E synthaseHomo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of extracellular matrix constituent secretionCarboxypeptidase B2Homo sapiens (human)
blood coagulationCarboxypeptidase B2Homo sapiens (human)
response to xenobiotic stimulusCarboxypeptidase B2Homo sapiens (human)
negative regulation of plasminogen activationCarboxypeptidase B2Homo sapiens (human)
protein catabolic processCarboxypeptidase B2Homo sapiens (human)
negative regulation of fibrinolysisCarboxypeptidase B2Homo sapiens (human)
cellular response to glucose stimulusCarboxypeptidase B2Homo sapiens (human)
liver regenerationCarboxypeptidase B2Homo sapiens (human)
negative regulation of hepatocyte proliferationCarboxypeptidase B2Homo sapiens (human)
proteolysisCarboxypeptidase B2Homo sapiens (human)
fibrinolysisCarboxypeptidase B2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
glutathione transferase activityProstaglandin E synthaseHomo sapiens (human)
glutathione peroxidase activityProstaglandin E synthaseHomo sapiens (human)
prostaglandin-D synthase activityProstaglandin E synthaseHomo sapiens (human)
protein bindingProstaglandin E synthaseHomo sapiens (human)
glutathione bindingProstaglandin E synthaseHomo sapiens (human)
prostaglandin-E synthase activityProstaglandin E synthaseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
zinc ion bindingCarboxypeptidase B2Homo sapiens (human)
metallocarboxypeptidase activityCarboxypeptidase B2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
nuclear envelope lumenProstaglandin E synthaseHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
perinuclear region of cytoplasmProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
extracellular regionCarboxypeptidase B2Homo sapiens (human)
extracellular exosomeCarboxypeptidase B2Homo sapiens (human)
extracellular spaceCarboxypeptidase B2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (172)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID683094Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX22012European journal of medicinal chemistry, Nov, Volume: 57Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.
AID340310Inhibition of human cyclooxygenase 22008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID184399Percentage inhibition of the prostaglandin synthesis was measured in rats.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID286322Inhibition of PGE2 production in LPS-stimulated mouse RAW264.7 cells at 10 uM after 2 hrs2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prosta
AID1532665Inhibition of COX2 (unknown origin) using arachidonic acid as substrate preincubated for 20 mins followed by substrate addition measured at 1 sec interval up to 60 secs by chemiluminescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Anti-inflammatory activity of triazine derivatives: A systematic review.
AID1617647Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
AID1532669Inhibition of recombinant human COX2 assessed as decrease in PGE2 release after 10 mins by ELISA2019European journal of medicinal chemistry, Jan-15, Volume: 162Anti-inflammatory activity of triazine derivatives: A systematic review.
AID402403Inhibition of COX1-catalyzed prostaglandin biosynthesis 10 mins of preincubation1998Journal of natural products, Oct, Volume: 61, Issue:10
Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis.
AID399406Selectivity ratio of IC50 for sheep placental cotyledons COX2 to IC50 for bovine seminal microsomal COX1 preincubated for 10 mins1998Journal of natural products, Jan, Volume: 61, Issue:1
Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
AID160570Inhibitory activity against murine Prostaglandin G/H synthase 2.2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities.
AID457533Inhibition of COX1 in mouse RAW264.7 cells by enzyme immunoassay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-alpha production.
AID333176Inhibition of PGE2 production in human HaCaT cells after 24 hrs by RIA2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID1322363Inhibition of mPGES-1 in mouse RAW264.7 cells assessed as reduction in LPS-induced PGE2 production at 3 uM after 24 hrs relative to control2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Synthesis, structure determination, and biological evaluation of phenylsulfonyl hydrazide derivatives as potential anti-inflammatory agents.
AID161674Tested for inhibition against Prostaglandin G/H synthase 11994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors.
AID469009Inhibition of COX2 at 100 uM after 15 mins2009Journal of natural products, Oct, Volume: 72, Issue:10
Monoterpenoid indole alkaloids from Alstonia yunnanensis.
AID1183834Inhibition of IFN-gamma/LPS-induced PGE2 production in mouse RAW264.7 cells at 50 uM after 17 to 20 hrs by EIA method2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of prostaglandin E(2) production by synthetic minor prenylated chalcones and flavonoids: synthesis, biological activity, crystal structure, and in silico evaluation.
AID1244193Inhibition of rat seminal vesicles COX-1 using arachidonic acid as substrate at 50 ug/ml preincubated for 5 mins followed by substrate addition after 20 mins by competitive PGE2 EIA method2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis of new 4-phenylpyrimidine-2(1H)-thiones and their potency to inhibit COX-1 and COX-2.
AID489468Inhibition of COX-2-mediated PGE2 production in LPS-induced mouse RAW 264.7 cells at 10 uM after 24 hrs by EIA2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
1,5-Diarylimidazoles with strong inhibitory activity against COX-2 catalyzed PGE2 production from LPS-induced RAW 264.7 cells.
AID1125686Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-22014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.
AID358219Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as PGE2 accumulation at 10 uM after 20 hrs by RIA relative to control2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID418268Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study.
AID46859In vitro activity at a concentration of 10 uM against Prostaglandin G/H synthase 21999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Synthesis and pharmacological evaluation of some 8-cyanopyrido[3', 2':4,5]thieno[3,2-d]triazine derivatives as inhibitors of nitric oxide and eicosanoid biosynthesis.
AID1172901Inhibition of COX2 (unknown origin) using arachidonic acid as substrate at 0.05 to 0.5 uM after 10 mins by luminometry2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and characterization of norbelladine, a precursor of Amaryllidaceae alkaloid, as an anti-inflammatory/anti-COX compound.
AID1183836Cytotoxicity against mouse RAW264.7 cells assessed as cell viability by MTT assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of prostaglandin E(2) production by synthetic minor prenylated chalcones and flavonoids: synthesis, biological activity, crystal structure, and in silico evaluation.
AID1195153Inhibition of human recombinant COX-2 using PGH2 as substrate incubated for 10 mins prior to arachidonic acid addition measured after 2 mins by EIA2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID166386Evaluated for inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and inhibitory activity against COX-2 catalyzed prostaglandin production of chrysin derivatives.
AID179689Percentage of gastric damage was measured in rats.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID1125683Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.
AID500941Inhibition of COX2 in human K562 cells assessed as blockade of AML1-ETO protein-dependent erythroid differentiation after 4 days by benzidine staining method2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID1173017Inhibition of human recombinant COX2 in cell-free system by enzyme immunoassay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and PGE₂ production inhibition of s-triazine derivatives as a novel scaffold in RAW 264.7 macrophage cells.
AID162015IC50 against ovine Prostaglandin G/H synthase 11999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID177102ED50 was measured by CFE assay method.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID233584Ratio of IC50 of COX-1 to COX-2.1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
AID457534Inhibition of COX2 in mouse RAW264.7 cells by enzyme immunoassay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-alpha production.
AID260816Inhibition of CYP450 aromatase activity in SK-BR-3 cells2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
AID54710Inhibitory concentration required against COX-2 activity in intact human monocytes1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID315992Inhibition of COX2 in human whole blood assessed as effect on LPS-stimulated PGE2 production2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides.
AID1322366Inhibition of recombinant human COX2 by enzyme immunoassay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Synthesis, structure determination, and biological evaluation of phenylsulfonyl hydrazide derivatives as potential anti-inflammatory agents.
AID232419Ratio of inhibition of COX-1 to COX-22000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
AID1351049Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production after 24 hrs by enzyme immunoassay2017European journal of medicinal chemistry, Dec-01, Volume: 141Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID160060Inhibitory effect on production of (COX-1) thromboxane B2 (TXB2) in human platelet cells2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
AID177103ED50 was measured by hyperalgesia assay method.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID500942Inhibition of COX2-mediated AE beta-casein/TCF signaling in human K562 cells harboring AML1-ETO protein at 75 uM by luciferase reporter assay relative to control2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID1351046Cytotoxicity against mouse RAW264.7 cells after 4 hrs by MTT assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1173021Inhibition of COX1 (unknown origin)2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and PGE₂ production inhibition of s-triazine derivatives as a novel scaffold in RAW 264.7 macrophage cells.
AID427903Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as PGE2 production at 10 uM treated 1 hr before LPS challenge measured after 24 hrs by enzyme immunoassay (RVb=11.5 +/- 0.36 uM)2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Phenolic glycosides from Alangium salviifolium leaves with inhibitory activity on LPS-induced NO, PGE(2), and TNF-alpha production.
AID1195152Inhibition of ovine recombinant COX-1 using PGH2 as substrate incubated for 10 mins prior to arachidonic acid addition measured after 2 mins by EIA2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID399407Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production at 100 uM preincubated for 10 mins1998Journal of natural products, Jan, Volume: 61, Issue:1
Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
AID637532Inhibition of mPGES-1 in human A549 cell microsomes assessed as conversion of PGH2 into PGE2 at 0 degC after 5 mins by HPLC-UV analysis2012European journal of medicinal chemistry, Feb, Volume: 48Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1.
AID620116Inhibition of microsomal PGES2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Novel human mPGES-1 inhibitors identified through structure-based virtual screening.
AID1125684Inhibition of ovine COX-1 assessed as decrease in PGH2 production using arachidonic acid as substrate treated with enzyme for 10 mins prior to substrate challenge for 2 mins by enzyme immunoassay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.
AID228022Inhibitory effect on production of (COX-2) prostaglandin E2 (PGE2) in human IL1-beta stimulated synovial cells2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
AID405533Inhibition of mPGES12008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID1688229Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction in LPS-induced PGE2 production at 10 nM incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA (Rvb = 33.64 ng/ml)2020European journal of medicinal chemistry, Feb-15, Volume: 188Thiazolidine-2,4-dione-based irreversible allosteric IKK-β kinase inhibitors: Optimization into in vivo active anti-inflammatory agents.
AID161472IC50 value against Prostaglandin G/H synthase 1 of human platelet rich plasma1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID1564058Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production at 10 nM preincubated for 1 hr followed by LPS addition and measured after 24 hrs by EIA relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators.
AID1267526Suppression of PGE2 production in LPS-induced mouse RAW264.7 cells after 24 hrs by enzyme immunoassay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Hit-to-lead optimization of phenylsulfonyl hydrazides for a potent suppressor of PGE2 production: Synthesis, biological activity, and molecular docking study.
AID1063491Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production administered 1 hr prior to LPS-challenge measured after 24 hrs by EIA2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Synthesis of tricyclic fused coumarin sulfonates and their inhibitory effects on LPS-induced nitric oxide and PGE2 productions in RAW 264.7 macrophages.
AID358218Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as nitrite accumulation after 20 hrs by fluorimetry2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID260819Reduction in CYP19 mRNA expression in SKBr3 cells after 24h exposure to 25uM relative to control2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
AID162497In vitro inhibitory activity against Prostaglandin G/H synthase 2 (COX-2) in human1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
Structure-based design of COX-2 selectivity into flurbiprofen.
AID333175Inhibition of PGE2 production in human HaCaT cells at 5 uM after 24 hrs by RIA2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID46862IC50 value against Prostaglandin G/H synthase 2 of murine J774A.1 cell line1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID1367567Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production pretreated for 1 hr followed by LPS addition measured after 24 hrs2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Inhibitory effect of moschamine isolated from Carthamus tinctorius on LPS-induced inflammatory mediators via AP-1 and STAT1/3 inactivation in RAW 264.7 macrophages.
AID612351Inhibition of human recombinant COX2 at 5 uM incubated for 10 mins by enzyme immunoassay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro.
AID192889Percentage of gastric damage was measured in rats.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID500925Inhibition of COX2-mediated decrease in gata1 expression in heterozygous transgenic zebrafish embryo assessed as restoration of gata1 level at 25 uM by in-situ hybridization analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID333177Cytotoxicity against human HaCaT cells assessed as LDH release at 5 uM after 24 hrs2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID177368ED50 measured by CFE assay1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID475085Inhibition of sheep placental cotyledens COX2 assessed as PGE2 level by EIA2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Derivatives of schisandrin with increased inhibitory potential on prostaglandin E(2) and leukotriene B(4) formation in vitro.
AID1263179Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production at 3 uM for 1 hr followed by stimulation with LPS for 24 hrs by SDS-PAGE analysis2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.
AID1322365Inhibition of ovine COX1 by enzyme immunoassay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Synthesis, structure determination, and biological evaluation of phenylsulfonyl hydrazide derivatives as potential anti-inflammatory agents.
AID162021In vitro inhibitory activity against Prostaglandin G/H synthase 1 in sheep1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
Structure-based design of COX-2 selectivity into flurbiprofen.
AID162337Effective dose for inhibition of Prostaglandin G/H synthase 21994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors.
AID704816Antiangiogenic activity against VEGFA-stimulated capillary differentiation in HUVEC after 18 hrs by matrigel assay2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.
AID1322364Inhibition of mPGES-1 in mouse RAW264.7 cells assessed as reduction in LPS-induced PGE2 production after 24 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Synthesis, structure determination, and biological evaluation of phenylsulfonyl hydrazide derivatives as potential anti-inflammatory agents.
AID500922Inhibition of COX2-mediated decrease in gata1 expression in heat-stimulated heterozygous transgenic zebrafish embryo assessed as restoration of gata1 level at 25 uM by in-situ hybridization analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID234944Ratio of IC50 for COX-1 and COX-2 binding inhibitors1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors.
AID1353256Inhibition of COX-2 in mouse RAW264.7 cells assessed as reduction in PGE2 production at 5 uM preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by enzyme immunoassay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146New selective cyclooxygenase-2 inhibitors from cyclocoumarol: Synthesis, characterization, biological evaluation and molecular modeling.
AID161335In vitro inhibition of prostaglandin G/H synthase 1.1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
AID683131Inhibition of COX2 expression in PMA-Ion-stimulated human PBL at 5 uM after 20 hrs by Western blot analysis2012European journal of medicinal chemistry, Nov, Volume: 57Sulfonilamidothiopyrimidone and thiopyrimidone derivatives as selective COX-2 inhibitors: synthesis, biological evaluation, and docking studies.
AID427630Inhibition of COX2 in sheep placental vesicle by enzyme immunoassay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation.
AID1173015Inhibition of PGE2 production in LPS-induced mouse RAW264.7 cells2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and PGE₂ production inhibition of s-triazine derivatives as a novel scaffold in RAW 264.7 macrophage cells.
AID704833Antitumor activity against VEGFA-stimulated mouse highly metastatic LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 5 mg/kg, sc qd for 18 days relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.
AID134147PGE-2 levels were assayed in inflamed paw after 5 hr carrageenan paw edema test in mice2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Solid-phase synthesis and inhibitory effects of some pyrido[1,2-c]pyrimidine derivatives on leukocyte formations and experimental inflammation.
AID1650938Antiinflammatory activity against murine RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production at 10 nM preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by EIA relative to control2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Inhibitory effects of triarylpyrazole derivatives on LPS-induced nitric oxide and PGE
AID161471IC50 against Prostaglandin G/H synthase 1 from human platelet rich plasma1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID193141Percentage inhibition of the prostaglandin synthesis was measured in rats.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID162016IC50 value against ovine Prostaglandin G/H synthase 11999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID162346In vitro inhibition of prostaglandin G/H synthase 2 (COX-2).1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
AID221439Antiinflammatory activity, assessed by the carrageenan paw edema test in mice2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Solid-phase synthesis and inhibitory effects of some pyrido[1,2-c]pyrimidine derivatives on leukocyte formations and experimental inflammation.
AID1063480Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production at 3 uM administered 1 hr prior to LPS-challenge measured after 24 hrs by EIA2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Synthesis of tricyclic fused coumarin sulfonates and their inhibitory effects on LPS-induced nitric oxide and PGE2 productions in RAW 264.7 macrophages.
AID1195154Selectivity ratio of IC50 for ovine recombinant COX-1 to IC50 for human recombinant COX-22015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies.
AID510445Inhibition of sheep COX2 by spectrophotometry2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID320936Inhibition of aromatase in human SKBR3 cells by tritiated water release assay2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.
AID6732The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID491942Inhibition of COX2 by microplate reader2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Triterpene saponins from Clematis chinensis and their potential anti-inflammatory activity.
AID161677The compound was evaluated for its inhibitory activity against Prostaglandin G/H synthase 1 using monocytes-like cells2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID487177Inhibition of human recombinant COX2 assessed as PGE2 level at 50 uM by ELISA2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and cyclooxygenase inhibitory activities of some N-acylhydrazone derivatives of isoxazolo[4,5-d]pyridazin-4(5H)-ones.
AID315991Inhibition of COX1 in human whole blood assessed as effect on A-23187-stimulated TxB2 production2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides.
AID162669The compound was evaluated for its inhibitory activity against Prostaglandin G/H synthase 2 using osteosarcomes cells2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID402402Inhibition of COX2-catalyzed prostaglandin biosynthesis after 10 mins of preincubation1998Journal of natural products, Oct, Volume: 61, Issue:10
Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis.
AID1125685Inhibition of human recombinant COX-2 assessed as decrease in PGH2 production using arachidonic acid as substrate treated with enzyme for 10 mins prior to substrate challenge for 2 mins by enzyme immunoassay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.
AID357982Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as nitrite accumulation at 10 uM after 20 hrs by fluorimetry relative to control2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID399405Inhibition of sheep placental cotyledons COX2 assessed as PGE2 production preincubated for 10 mins1998Journal of natural products, Jan, Volume: 61, Issue:1
Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
AID1183835Inhibition of IFN-gamma/LPS-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by EIA method2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of prostaglandin E(2) production by synthetic minor prenylated chalcones and flavonoids: synthesis, biological activity, crystal structure, and in silico evaluation.
AID333171Inhibition of TPA-induced ROS production in human neutrophils at 5 uM by chemiluminescence2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID683092Inhibition of ovine COX1 assessed as inhibition of PGF2alpha production from PGH2 by enzyme immuno assay2012European journal of medicinal chemistry, Nov, Volume: 57Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.
AID260817Inhibition of aromatase activity in human placental microsomes at 5 uM2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
AID683093Inhibition of human recombinant COX2 assessed as inhibition of PGF2alpha production from PGH2 by enzyme immunoassay2012European journal of medicinal chemistry, Nov, Volume: 57Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.
AID193990Lesion frequency was measured in rats.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID500929Inhibition of COX2 in heterozygous transgenic zebrafish embryo assessed as MPO-positive granulocytic cell accumulation at 25 uM by in situ hybridization analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID637535Inhibition of mPGES-12012European journal of medicinal chemistry, Feb, Volume: 48Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1.
AID161998Inhibitory activity against murine prostaglandin G/H synthase 1.2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities.
AID162143Inhibition of the ovine Prostaglandin G/H synthase 1 was determined by thin-layer chromatography assay2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors.
AID161850Selectivity as ratio of the inhibitory concentration values Prostaglandin G/H synthase 1 to Prostaglandin G/H synthase 22002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID500931Inhibition of COX2 in heat-stimulated heterozygous transgenic zebrafish embryo assessed as MPO-positive granulocytic cell accumulation at 25 uM by in situ hybridization analysis in presence of PGE22009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID134146PGE-2 levels were assayed in LPS stimulated RAW 264.7 macrophages for 20h in either presence or absence of compound2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Solid-phase synthesis and inhibitory effects of some pyrido[1,2-c]pyrimidine derivatives on leukocyte formations and experimental inflammation.
AID1125139Selectivity ratio IC50 for ovine COX1 to IC50 for human recombinant COX22014European journal of medicinal chemistry, Apr-22, Volume: 771-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity.
AID333173Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation at 5 uM after 24 hrs2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID177369ED50 measured by hyperalgesia assay1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID510446Selectivity index, ratio of IC50 for sheep COX1 to IC50 for sheep COX22010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID1173019Inhibition of PGE2 production in LPS-induced mouse RAW264.7 cells at 3 uM2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and PGE₂ production inhibition of s-triazine derivatives as a novel scaffold in RAW 264.7 macrophage cells.
AID1125138Inhibition of human recombinant COX2 assessed as prostaglandin F2alpha level2014European journal of medicinal chemistry, Apr-22, Volume: 771-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity.
AID1353255Inhibition of COX-2 in mouse RAW264.7 cells assessed as reduction in PGE2 production at 1 uM preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by enzyme immunoassay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146New selective cyclooxygenase-2 inhibitors from cyclocoumarol: Synthesis, characterization, biological evaluation and molecular modeling.
AID46861IC50 value was determined against Prostaglandin G/H synthase 2 of J7744A.1 cell lines.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID260820Inhibitory activity against COX22006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
AID403340Inhibition of COX22005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID292899Cytotoxicity against human SK-BR-3 cells after 24 hrs by MTT assay relative to NS3982007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer.
AID1244194Inhibition of sheep placental cotyledons COX-2 using arachidonic acid as substrate at 50 ug/ml preincubated for 5 mins followed by substrate addition after 20 mins by competitive PGE2 EIA method2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis of new 4-phenylpyrimidine-2(1H)-thiones and their potency to inhibit COX-1 and COX-2.
AID336477Inhibition of COX2 by scintillation proximity assay2002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID399404Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production preincubated for 10 mins1998Journal of natural products, Jan, Volume: 61, Issue:1
Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
AID185328Lesion frequency measured in rats1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID1353257Inhibition of COX-2 in mouse RAW264.7 cells assessed as reduction in PGE2 production at 20 uM preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by enzyme immunoassay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146New selective cyclooxygenase-2 inhibitors from cyclocoumarol: Synthesis, characterization, biological evaluation and molecular modeling.
AID717377Inhibition of microsomal PGES1 using PGH2 as substrate by RP-HPLC method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of novel mPGES-1 inhibitors through screening of a chemical library.
AID286320Inhibition of PGE2 production in LPS-stimulated mouse RAW264.7 cells at 10 uM after 18 hrs2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prosta
AID358220Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as PGE2 accumulation after 20 hrs by RIA2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID46852IC50 against recombinant human Prostaglandin G/H synthase 21999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
AID176242Inhibitory effect for increase in plasma prostaglandin E2 (PGE2) level after arachidonic acid (AA) injection into, COX-1 non-lipopolysaccharide-treated rats2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
AID315993Selectivity for human COX2 over human COX1 by human whole blood assay2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides.
AID1474747Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Identification and structure activity relationship of novel flavone derivatives that inhibit the production of nitric oxide and PGE
AID166388Inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells at concentration of 10 uM2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and inhibitory activity against COX-2 catalyzed prostaglandin production of chrysin derivatives.
AID411439Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells at 0.1 uM by ELISA2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis of biflavones having a 6-O-7'' linkage and effects on cyclooxygenase-2 and inducible nitric oxide synthase.
AID402404Ratio of IC50 for COX2 to IC50 for COX11998Journal of natural products, Oct, Volume: 61, Issue:10
Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis.
AID176241Inhibitory effect for increase in plasma prostaglandin E2 (PGE2) level after arachidonic acid (AA) injection into COX-2 lipopolysaccharide-treated rats2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
AID1351047Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID46853Inhibition of recombinant human prostaglandin G/H synthase 2 (COX-2)1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
AID132323Ability to inhibit the accumulation of PGE-2 in stimulated murine peritoneal macrophages1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Synthesis and pharmacological evaluation of some 8-cyanopyrido[3', 2':4,5]thieno[3,2-d]triazine derivatives as inhibitors of nitric oxide and eicosanoid biosynthesis.
AID418269Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study.
AID688618Inhibition of sheep placental COX2 assessed as PGE2 production by enzyme immunoassay2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.
AID461096Inhibition of potato tuber 5LOX by polarographic method2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
AID162665Tested for inhibition against Prostaglandin G/H synthase 21994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors.
AID510444Inhibition of sheep COX1 by spectrophotometry2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID134145PGE-2 level was assayed in RAW 264.7 macrophages after a 20h stimulation with LPS followed by incubation with compound and arachidonic acid for 2 hr2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Solid-phase synthesis and inhibitory effects of some pyrido[1,2-c]pyrimidine derivatives on leukocyte formations and experimental inflammation.
AID418267Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells at 10 uM by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study.
AID704817Antiangiogenic activity against VEGFA-stimulated cell proliferation in HUVEC after 48 hrs by BrdU incorporation assay2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.
AID453928Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production by EIA2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthesis and PGE(2) production inhibition of 1H-furan-2,5-dione and 1H-pyrrole-2,5-dione derivatives.
AID500927Inhibition of COX2 in heat-stimulated heterozygous transgenic zebrafish embryo assessed as MPO-positive granulocytic cell accumulation at 25 uM by in situ hybridization analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID132688Inhibitory activity against LPS stimulated RAW 264.7 macrophages2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Solid-phase synthesis and inhibitory effects of some pyrido[1,2-c]pyrimidine derivatives on leukocyte formations and experimental inflammation.
AID235171Selectivity ratio of COX-1 to that of COX-21999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
Structure-based design of COX-2 selectivity into flurbiprofen.
AID704826Antiangiogenic activity against VEGFA-stimulated mouse highly metastatic LLC cells xenografted in C57BL/6 mouse assessed as reduction of vessel formation at 5 mg/kg, sc qd for 7 days relative to control2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.
AID1353254Inhibition of COX-2 in mouse RAW264.7 cells assessed as reduction in PGE2 production at 10 uM preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by enzyme immunoassay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146New selective cyclooxygenase-2 inhibitors from cyclocoumarol: Synthesis, characterization, biological evaluation and molecular modeling.
AID1125137Inhibition of ovine COX1 assessed as prostaglandin F2alpha level2014European journal of medicinal chemistry, Apr-22, Volume: 771-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity.
AID260818Reduction in PGE2 levels in MDA-MB-231 cell2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
AID162641Inhibition of the human Prostaglandin G/H synthase 2 was determined by thin-layer chromatography assay2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors.
AID385238Inhibition of COX2 at 10 uM2008Journal of natural products, May, Volume: 71, Issue:5
Itosides J-N from Itoa orientalis and structure - anti-COX-2 activity relationship of phenolic glycosides.
AID1801084In vitro Cyclooxygenase Inhibition Assay from Article 10.1111/cbdd.12435: \\1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and u00DF-amyloid aggregation inhibitors: biological evaluation and in silico study.\\2015Chemical biology & drug design, Apr, Volume: 85, Issue:4
1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and β-amyloid aggregation inhibitors: biological evaluation and in silico study.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1345206Human COX-2 (Cyclooxygenase)2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,196)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's174 (14.55)18.2507
2000's735 (61.45)29.6817
2010's263 (21.99)24.3611
2020's24 (2.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.54 (24.57)
Research Supply Index7.11 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.25%)5.53%
Reviews8 (0.66%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,209 (99.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]